52 results about "Antibody affinity" patented technology

The application relates to the technical field of artificial intelligence, in particular to an antigen-antibody affinity prediction method, system and device, which comprises the following steps: performing feature extraction on amino acid sequence data of an antigen and an antibody, and generating a preliminary complex three-dimensional conformation through a prediction model; fusing and screening a plurality of preliminary complex three-dimensional conformations to determine an intermediate complex three-dimensional conformation; optimizing a binding interface of the intermediate complex three-dimensional conformation based on molecular dynamics simulation and a reinforcement learning algorithm to obtain a final optimized conformation; performing energy decomposition based on a molecular force field principle to obtain key energy parameters, and obtaining a binding free energy through an affinity prediction deep neural network based on the key energy parameters and energy characteristics determined by the molecular dynamics simulation; and when the binding free energy is higher than a judgment threshold, re-performing optimization and determining the binding free energy. In this way, the accuracy and reliability of prediction can be significantly improved on the basis of realizing full-process automation.

The invention relates to the technical field of biology, in particular to a method for improving affinity of a nano antibody based on computer-aided design. According to the method, a series of bioinformatics tools for nano antibody affinity maturation are investigated and researched in literatures, and part of databases, servers and software are optimized to construct a set of computer-aided design (CAD) nano antibody affinity improvement method by evaluating the operability and the improvement effect of the tools. In order to verify the effectiveness and universality of the method, based on the method, a high-affinity mutant nano antibody is virtually screened out of an Anti-Nectin-4 camel source nano antibody NBNT-1 and an Anti-PD-L1 shark source nano antibody NBNT4 screened in a synthetic library through model construction, model evaluation, site prediction, molecular docking, structural analysis, mutation prediction and mutation evaluation. Traditional in-vitro affinity maturation methods, such as error-prone PCR, are low in screening efficiency, large in randomness introduced by mutation, long in experimental period, large in workload and difficult to accurately optimize the affinity of target molecules. According to the method, various defects of a traditional in-vitro affinity maturation method are overcome, and the success rate and efficiency of affinity maturation are improved.

The invention belongs to the field of nano antibodies, and relates to an NKG2A antibody or an antigen-binding part thereof and application of the NKG2A antibody or the antigen-binding part thereof. The NKG2A antibody or an antigen binding part of the NKG2A antibody is composed of a heavy chain variable structural domain, and the amino acid sequence of a heavy chain CDR1 is X1YTSX2TNFF (SEQ ID NO: 39); the amino acid sequence of the heavy chain CDR2 is ISX3TGX4YT (SEQ ID NO: 40); and the amino acid sequence of the heavy chain CDR3 is AAGX5RX6GDNWEX7EX8SWFY (SEQ ID NO: 41). Compared with the prior art, the invention has the beneficial effects that the NKG2A antibody or the antigen binding part thereof is screened by using a biological genetic engineering technology, and the affinity of the antibody is better.

The invention provides a cTnI protein antibody. The cTnI protein antibody comprises an anti-human cTnI protein monoclonal antibody I, an anti-human cTnI protein monoclonal antibody II and / or an anti-human cTnI protein monoclonal antibody III, the antibody respectively comprises a light chain and a heavy chain; wherein the light chain sequence of the antibody I is as shown in SEQ ID NO.1, and the heavy chain sequence of the antibody I is as shown in SEQ ID NO.2; a light chain sequence of the antibody II is as shown in SEQ ID NO.3, and a heavy chain sequence of the antibody II is as shown in SEQ ID NO.4; the light chain sequence of the antibody III is as shown in SEQ ID NO.5, and the heavy chain sequence of the antibody III is as shown in SEQ ID NO.6. The invention also provides a latex enhanced immunoturbidimetric kit for quantitatively detecting the cTnI protein and a preparation method of the latex enhanced immunoturbidimetric kit. The invention has the advantages that the antibody affinity is high, the specificity is good, and a kit based on the antibody is high in sensitivity, good in specificity and strong in anti-interference capability.

The invention discloses an anti-MerTK antibody and an application of the anti-MerTK antibody. The invention also discloses nucleic acid for coding the antibody, a recombinant expression vector, a transformant, a preparation method of the antibody, a chimeric antigen receptor, an antibody drug conjugate, a pharmaceutical composition or a kit containing the antibody, and applications of the nucleic acid, the recombinant expression vector, the transformant, the chimeric antigen receptor, the antibody drug conjugate, the pharmaceutical composition or the kit in preparation of drugs for preventing and / or treating tumors. The antibody provided by the invention has high affinity, and can simultaneously block the interaction of the ligand GAS6-MerTK and the ligand protein S-MerTK, but does not block the interaction of the ligand TULP1-MerTK. And potential toxicity to the retina can be avoided when inhibition activity is exerted in vivo. In addition, the anti-human MerTK antibody provided by the invention can specifically and effectively inhibit phosphorylation of AKT in a Gas6-MerTK signal, and shows certain tumor inhibition activity in a mouse in-vivo model test.

This invention relates to a detection kit and preparation method for enhancing the detection efficacy of autoimmune encephalitis (CBA) antibodies. The kit comprises genetically engineered 293T cells stably integrating and co-expressing the eIF2α S52A mutant and HSP70, and transiently transfected with CBA-associated antigens. The preparation method includes constructing a co-expression vector, establishing a stable transfection cell line, stress preconditioning treatment, antigen transfection, and kit assembly. A method for assessing antibody affinity maturation using this kit is also provided. By synergistically modifying detection cells at three levels—translational regulation, protein folding, and anti-apoptosis—the invention significantly increases antigen expression, reduces apoptosis, and improves detection sensitivity and specificity. Furthermore, it integrates antibody affinity assessment into CBA detection for the first time, providing auxiliary information for clinical staging.

The invention discloses an MTBR-tau243 specific antibody and application of the MTBR-tau243 specific antibody in an Alzheimer's disease auxiliary diagnosis kit, belongs to the technical field of immunoassay, and provides an MTBR-tau243 targeted antibody and a chemiluminescence kit for detecting MTBR-tau243. The antibody is high in affinity, high in sensitivity and obviously shortened in production cycle, and is more suitable for being used as a core raw material to be applied to the field of in-vitro diagnostic reagents. The kit disclosed by the invention can be used for auxiliary diagnosis of diseases related to MTBR-tau243, such as Alzheimer's disease.

The present application relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is a protein expressed on the surface of regulatory T cells. The binding molecule provided by the present application can inhibit the function of regulatory T cells, thereby effectively preventing, improving or treating cancer, especially solid tumors. In addition, compared with commercially available antibodies against Lrig-1, the binding molecule provided by the present application can more effectively target Lrig-1 protein and show excellent binding affinity.

This application discloses a method for screening single B cells. The method provided in this application uses magnetic beads coated with IL-6 antigen, combined with fluorescently labeled secondary antibody, and employs droplet microfluidic technology to rapidly sort B cells. The obtained IL-6 positive B cells are then directly cultured, and the generated antibodies are subjected to ELISA and IL-6 antigen-antibody affinity detection to obtain the target cell line. The entire process is greatly simplified and the workload is significantly reduced.

The present application relates to the technical field of bio-chemical engineering, and particularly relates to a halogen-modified hapten for enhancing antibody affinity, and a preparation method and application thereof. The present application provides a halogen-modified sulfonamide hapten for enhancing antibody affinity, which is obtained by adopting halogen-modified sulfonamides, and the antibody prepared by the halogen-modified sulfonamide hapten has relatively high titer and affinity. The present application provides a new and effective approach for preparing high-affinity sulfonamide antibodies.

The invention relates to a trace hydroxyputrescine lysine protein detection method, which comprises: 1) preparing a sample to be detected, and slicing cells, body fluid or tissue; (2) sealing the sample by using Duolink sealing liquid; (3) diluting an anti-rabbit PLUS probe and an anti-mouse MINUS probe Merck and DUO92101 / DUO92102 in proportion by using a Duolinkantibody diluent, incubating with a product obtained in the previous step, and respectively combining a rabbit polyclonal antibody and a mouse monoclonal antibody through the PLUS / MINUS probe to provide a basis for a ligation reaction; (4) diluting ligase by using a Duolink ligation buffer solution according to the ratio, and incubating with the product in the step (3) at the temperature; 5) diluting an amplification enzyme with a Duolink amplification buffer solution in proportion, and incubating with a product obtained in the previous step; 6, a mounting medium containing DAPI is adopted for mounting, and imaging analysis is carried out through a fluorescence or confocal microscopy. The problem that due to the fact that the affinity of the antibody is insufficient and the protein expression quantity is low, the omission ratio of the trace hydroxyputrescine lysine modified protein is high can be well solved.

The invention relates to an AVRcap1b nano antibody and application thereof, and belongs to the field of biological medicines.The anti-AVRcap1b nano antibody is developed through multiple steps of detection, screening and the like by adopting a yeast two-hybrid screening system, the whole screening cost is greatly reduced compared with that of a traditional antibody, the research and development period is short, the requirements for the experimental environment and equipment are simple, and the applicability is wide. Compared with a traditional AVRcap1b antibody, the developed AVRcap1b nano antibody has the advantages that the molecular weight is smaller, the tissue permeability is better, meanwhile, the nano antibody is more stable, and the immunogenicity is low. In a word, the AVRcap1b nano antibody has outstanding advantages in the aspects of antibody affinity, targeting specificity, small molecule size, stability, modifiability, production cost and the like.

The invention provides an antigen-antibody affinity prediction method of a cross-modal fusion composite structure and sequence, and belongs to the technical field of natural language processing. Firstly, a data set of antigen-antibody affinity is obtained and divided into a training set, a verification set and a test set; secondly, constructing an antibody and antigen sequence information mining module; then constructing an antibody and antigen complex structure information mining module; secondly, inputting the multi-scale feature representation of the antibody and the antigen into a fusion layer to generate a steady affinity prediction result; and finally, comparing a predicted value with a true value, training the best parameter of the model, and storing the best parameter. Through multi-modal and multi-scale information extraction and cross-modal fusion, information interaction between two modals of the antigen and antibody sequence set structure is realized, and the precision and robustness of affinity prediction are improved.

The invention relates to an anti-CD33 single-domain antibody and application thereof. According to the invention, the anti-CD33 single-domain antibody specifically bound with CD33 is screened by using a biological gene engineering technology, and the antibody has good affinity and is used for treating hematological malignant tumors and other CD33 related diseases.

The application relates to the fields of biological medicine and antibody engineering technology, and particularly relates to a STAT3 hybridoma-derived antibody affinity maturation method based on computational biology, which comprises the following steps: (1) obtaining an antibody variable region sequence; (2) constructing STAT3 antigen and antibody models and evaluating; (3) performing antigen-antibody molecular docking and optimization, and screening out models; (4) performing docking model analysis, and obtaining potential saturation mutation sites; (5) performing site saturation mutation, and obtaining mutation results; (6) performing mutation site analysis, and determining final mutation sites; (7) amplifying a target fragment containing the mutation sites; (8) constructing a recombinant expression vector, and obtaining a reformed STAT3 recombinant antibody through eukaryotic expression and purification; and (9) performing relative affinity determination.

The invention relates to an AVRcap1b nano antibody and application thereof, and belongs to the field of biological medicines.The anti-AVRcap1b nano antibody is developed through multiple steps of detection, screening and the like by adopting a yeast two-hybrid screening system, the whole screening cost is greatly reduced compared with that of a traditional antibody, the research and development period is short, the requirements for the experimental environment and equipment are simple, and the applicability is wide. Compared with a traditional AVRcap1b antibody, the developed AVRcap1b nano antibody has the advantages that the molecular weight is smaller, the tissue permeability is better, meanwhile, the nano antibody is more stable, and the immunogenicity is low. In a word, the AVRcap1b nano antibody has outstanding advantages in the aspects of antibody affinity, targeting specificity, small molecule size, stability, modifiability, production cost and the like.

A compound or a salt thereof comprising: (A) an affinity polypeptide including an affinity moiety having affinity for a heavy chain CH2-CH3 interdomain region of an antibody; (B) a first antibody reactive group; and (C) a second antibody reactive group. The affinity polypeptide includes first and second amino acid residues each having a side chain amino group, and the first antibody reactive group and the second antibody reactive group are linked to the affinity polypeptide via linkers that are introduced into the side chain amino groups of the first and second amino acid residues each having the side chain amino group, respectively.

The invention belongs to the technical field of antigen-antibody affinity prediction, and discloses an antigen-antibody affinity prediction method and device.According to the antigen-antibody affinity prediction method and device, double-position coding is introduced, so that the modeling capacity of dynamic conformation and residue position sensitivity of antibody heavy-chain and light-chain CDR regions is remarkably enhanced, and a model can be used for predicting the antigen-antibody affinity under the condition that the model does not depend on three-dimensional structure data; the sequence diversity characteristics of the CDR region of the antibody can be accurately captured, so that the problem of omission of characterization of a functional region in a traditional sequence method is solved; the cross attention module breaks through the limitation of traditional linear splicing or weighted summation through a heavy chain-light chain-antigen three-way interaction mechanism, and explicitly models the complex interaction among the three. In addition, through hierarchical feature extraction of a deep separable convolution and self-attention hybrid architecture, the model realizes efficient modeling of a long-range dependency relationship.

The application discloses a UCH-L1 specific antibody and application thereof in an auxiliary diagnosis kit for traumatic brain injury, and belongs to the technical field of immune analysis. The application provides an antibody targeting UCH-L1 and a chemiluminescence kit for detecting UCH-L1. The antibody provided by the application has high affinity, high sensitivity and a significantly shortened production cycle, and is more suitable for being applied to the field of in-vitro diagnosis reagents as a core raw material. The kit disclosed by the application can be used for the auxiliary diagnosis of diseases related to UCH-L1, such as traumatic brain injury.

The present application relates to an AVRcap1b nanobody and application thereof, and belongs to the field of biological medicine, wherein the present application develops an anti-AVRcap1b nanobody through multiple steps such as detection and screening by using a yeast two-hybrid screening system, the screening cost is greatly reduced compared with traditional antibodies, the research and development cycle is shorter, the requirements for experimental environment and equipment are simpler, and the applicability is wide. Compared with traditional AVRcap1b antibodies, the developed AVRcap1b nanobody has smaller molecular weight, better tissue permeability, is more stable, and has low immunogenicity. In summary, the AVRcap1b nanobody has outstanding advantages in terms of antibody affinity and targeting specificity, small molecule size, stability and transformability, production cost and the like.

The invention discloses an alpha-syn oligomer specific antibody and application thereof in a Parkinson's disease auxiliary diagnosis kit, belongs to the technical field of immunoassay, and provides an antibody targeting an alpha-syn oligomer and a chemiluminescence kit for detecting the alpha-syn oligomer. Amino acid sequences of heavy chains CDRH1-CDRH3 of the antibody are respectively and sequentially shown as SEQ ID NO: 1-SEQ ID NO: 3, an amino acid sequence of a light chain CDRL1 is shown as SEQ ID NO: 4, an amino acid sequence of a light chain CDRL2 is LA, and an amino acid sequence of a light chain CDRL3 is shown as SEQ ID NO: 5. The antibody is high in affinity, high in sensitivity, obviously shortened in production cycle and more suitable for being used as a core raw material to be applied to the field of in-vitro diagnostic reagents.

The invention discloses a UCH-L1 specific antibody and application of the UCH-L1 specific antibody in a traumatic brain injury auxiliary diagnosis kit, belongs to the technical field of immunoassay, and provides a UCH-L1 targeting antibody and a chemiluminescence kit for detecting UCH-L1. The antibody is high in affinity, high in sensitivity and obviously shortened in production cycle, and is more suitable for being used as a core raw material to be applied to the field of in-vitro diagnostic reagents. The kit disclosed by the invention can be used for auxiliary diagnosis of diseases related to UCH-L1, such as traumatic brain injury.

The invention belongs to the field of nano antibodies, and particularly relates to a nano antibody specifically combined with CD161 and application of the nano antibody. The nano antibody is specifically combined with the human CD161 protein at an EC50 value which is not greater than 0.5 nM; and the nano antibody, the CLEC2D and the human CD161 protein are competitively combined. Compared with the prior art, the method has the beneficial effects that the nano antibody specifically combined with CD161 is screened by using a biological genetic engineering technology, and the affinity and the specificity of the antibody are relatively good.

According to the CGRP and SP antibodies and the application thereof in virus infection resistance, CGRP polypeptide and SP polypeptide are optimized and combined respectively, the expression quantity and immunogenicity are greatly improved, the optimal CGRP and SP monoclonal antibodies are screened out through a phage display technology, the optimal antibodies are high in affinity and specificity, and the monoclonal antibodies can be used for resisting virus infection. When the polypeptide is used in combination, the polypeptide shows extremely high capability of resisting DNA / RNA virus infection in a synergistic manner, the expression of macrophage interferon and the expression of inflammatory factors are remarkably improved, and the polypeptide has important clinical application value.

Provided are a uPAR antibody and a use in the treatment of cancer and immune-related diseases. The selected uPAR antibody has strong affinity, good stability, and strong blocking capability, can significantly mediate the killing capability of immune cells against tumor cells, and can be used for the diagnosis, treatment, and prognosis of tumors expressing uPAR and immune-related diseases.

The invention relates to an AVRcap1b nano antibody and application thereof, and belongs to the field of biological medicines.The anti-AVRcap1b nano antibody is developed through multiple steps of detection, screening and the like by adopting a yeast two-hybrid screening system, the whole screening cost is greatly reduced compared with that of a traditional antibody, the research and development period is short, the requirements for the experimental environment and equipment are simple, and the applicability is wide. Compared with a traditional AVRcap1b antibody, the developed AVRcap1b nano antibody has the advantages that the molecular weight is smaller, the tissue permeability is better, meanwhile, the nano antibody is more stable, and the immunogenicity is low. In a word, the AVRcap1b nano antibody has outstanding advantages in the aspects of antibody affinity, targeting specificity, small molecule size, stability, modifiability, production cost and the like.

The application discloses an MTBR-tau243 specific antibody and application thereof in an Alzheimer's disease auxiliary diagnosis kit, and belongs to the technical field of immune analysis. The application provides an antibody targeting MTBR-tau243 and a chemiluminescence kit for detecting MTBR-tau243. The antibody provided by the application has high affinity, high sensitivity and a significantly shortened production cycle, and is more suitable for being applied to the field of in-vitro diagnosis reagents as a core raw material. The kit disclosed by the application can be used for the auxiliary diagnosis of diseases related to MTBR-tau243, such as Alzheimer's disease.

The present invention relates to technology for easily chemically modifying a heavy chain CH1 region in a constituent unit of an antibody. More specifically, the present invention relates to: a compound which contains (A) an affinity polypeptide containing an affinity moiety having an affinity for the heavy chain CH1 region of the antibody, and (B) a group that is reactive with the antibody; or a salt thereof.

The application discloses an np-Tau217 specific antibody and application thereof in an Alzheimer's disease auxiliary diagnosis kit, and belongs to the technical field of immune analysis. The application provides an antibody targeting np-Tau217 and a chemiluminescence kit for detecting np-Tau217. The antibody or antigen binding fragment thereof specifically binds to np-Tau217, the amino acid sequences of the heavy chain CDRH1-CDRH3 are sequentially shown as SEQ ID NO:1-SEQ ID NO:3, the amino acid sequence of the light chain CDRL1 is shown as SEQ ID NO:4, the amino acid sequence of the light chain CDRL2 is DA, and the amino acid sequence of the light chain CDRL3 is shown as SEQ ID NO:5. The antibody has high affinity, high sensitivity and a significantly shortened production cycle, and is more suitable for being applied to the field of in-vitro diagnosis reagents as a core raw material. The kit disclosed by the application can be used for the auxiliary diagnosis of diseases related to np-Tau217, such as Alzheimer's disease.

The disclosure provides an engineered escherichia coli and application thereof, and relates to the technical field of biotechnology.The engineered bacteria provided by the disclosure knock out the natural type I pilus, can effectively reduce the non-specific targeting adhesion rate of the engineered bacteria without changing the growth condition and morphology of the engineered bacteria, can realize flexible targeting of various target cells by replacing the single-domain antibody sequence of the extracellular artificially synthesized adhesin (intimin or YeeJ), and has the potential to become a precision treatment toolkit.The antigen-antibody combination can be visualized at the cell level, and the antigen-antibody combination is convenient and time-saving, and provides a powerful tool for evaluating the antibody affinity in the antibody screening work.The engineered bacteria provided by the disclosure can specifically colonize inside tumors, have a certain tumor growth inhibition effect, and have high biological safety.Further, on the basis of targeted adhesion, the cytotoxic molecules are increased, can accelerate the induction of tumor cell apoptosis, and have a significant anticancer effect.